ADP-dependent glucokinase controls metabolic fitness in prostate cancer progression
RESEARCH|Updated:2025-12-13
|
ADP-dependent glucokinase controls metabolic fitness in prostate cancer progression
“In the field of prostate cancer treatment, researchers have identified ADP-dependent glucokinase (ADPGK) as a crucial target. The study found that high ADPGK expression is associated with poor survival outcomes in prostate cancer patients. ADPGK accelerates cancer glycolysis and progression by activating the ALDOC-AMPK signaling pathway, laying a foundation for the construction of a new treatment and prognosis evaluation system for prostate cancer.”
Military Medical ResearchVol. 11, Issue 5, Pages: 643-662(2024)
Affiliations:
1.Department of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
2.Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
3.Animal Experimental Center, West China Hospital, Sichuan University, Chengdu 610041, China
4.Research Core Facility, West China Hospital, Sichuan University, Chengdu 610041, China
Cite this article as: Xu H, Li YF, Yi XYL, Zheng XN, Yang Y, Wang Y, et al. ADP-dependent glucokinase controls metabolic fitness in prostate cancer progression. Mil Med Res. 2023;10(1):64.
DOI:
Cite this article as: Xu H, Li YF, Yi XYL, Zheng XN, Yang Y, Wang Y, et al. ADP-dependent glucokinase controls metabolic fitness in prostate cancer progression. Mil Med Res. 2023;10(1):64. DOI: 10.1186/s40779-023-00500-9.
ADP-dependent glucokinase controls metabolic fitness in prostate cancer progression